SCM
MAIA icon

Solas Capital Management’s MAIA Biotechnology MAIA Stock Holding History

Solas Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Sell
3,030,845
-1,266,159
-29% -$1.68M 2.34% 16
2026
Q1 		$6.02M Buy
+4,297,004
New +$7.92M 3.46% 12

Other funds holding MAIA

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Solas Capital Management's MAIA Position: Q2 2026 in Review

Solas Capital Management reduced its MAIA Biotechnology (MAIA) stake by 29% in Q2 2026, selling an estimated $1.68M and leaving 3,030,845 shares worth $4.36M. The position accounts for 2.34% of the portfolio, ranked #16.

Solas Capital Management first reported a position in MAIA in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.02M in Q1 2026. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • Solas Capital Management held 3,030,845 shares of MAIA Biotechnology worth $4.36M as of Q2 2026.
  • Solas Capital Management sold 1,266,159 MAIA Biotechnology shares in Q2 2026, an estimated $1.68M.
  • MAIA Biotechnology made up 2.34% of Solas Capital Management's portfolio in Q2 2026, its #16 holding.
  • Solas Capital Management first reported a position in MAIA Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • Solas Capital Management's MAIA Biotechnology position peaked at $6.02M in Q1 2026.
  • 36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Solas Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.